Dipeptidyl Peptidase-4 Inhibitors Associated with Lower Psoriatic Disease Risk in Type 2 Diabetes: A 13-Year Nationwide Cohort Study with Mechanistic Validation
DOI:
https://doi.org/10.2340/actadv.v105.44343Keywords:
dipeptidyl peptidase 4 inhibitors, cutaneous psoriasis, Psoriatic Arthritis, Population-based cohort study, type 2 diabetes mellitusAbstract
Psoriatic disease, encompassing psoriasis and -psoriatic arthritis, is a chronic inflammatory condition with bidirectional associations with type 2 diabetes mellitus. Current evidence regarding dipeptidyl peptidase-4 inhibitors’ effects on psoriatic disease presents conflicting findings, with the impact on psoriatic arthritis remaining unexplored. This study aimed to investigate the association between dipeptidyl peptidase-4 inhibitors use and psoriatic disease risk in diabetic patients. A nationwide population-based cohort study was conducted using Taiwan’s National Health Insurance Research Database (2009–2021), including 78,865 patients with type 2 diabetes mellitus: 15,773 dipeptidyl peptidase-4 inhibitors users and 63,092 matched controls. Primary outcomes were incident psoriasis and psoriatic arthritis. During a median follow-up of 7.08 years, 393 cases developed psoriatic disease: 51 cases in the dipeptidyl peptidase-4 inhibitors cohort vs 342 cases in controls. Dipeptidyl peptidase-4 inhibitors therapy was associated with significantly lower psoriatic disease risk (adjusted hazard ratio 0.583, 95% confidence interval 0.430–0.696). Individual dipeptidyl peptidase-4 inhibitors demonstrated varying protective effects, with alogliptin showing the strongest protection. In vitro experiments confirmed that dipeptidyl peptidase-4 inhibitors significantly attenuated inflammatory responses in human skin cells. This large-scale nationwide study demonstrates that dipeptidyl peptidase-4 inhibitors use is associated with a 41.7% lower risk in psoriatic disease in diabetic patients.
Downloads
References
Boehncke WH, Schon MP. Psoriasis. Lancet 2015; 386: 983–994. DOI: https://doi.org/10.1016/S0140-6736(14)61909-7
Iskandar IY, Teng-Chou C, Li-Chia C, Meng-Sui L, Yen-Yun Y, Ting-Chun W, et al. Incidence, prevalence, and mortality of people with psoriasis and psoriatic arthritis in Taiwan: a nationwide cohort study. Acta Derm Venereol 2022; 102: adv00807.
Chiu H-Y, Hung C-J, Muo C-H, Fan K-C, Sung F-C. The bidirectional association between type 2 diabetes and psoriasis: two retrospective cohort studies. Indian J Dermatol Venereol Leprol 2020; 86: 366. DOI: https://doi.org/10.4103/ijdvl.IJDVL_428_18
Ohnuma K, Dang NH, Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol 2008; 29: 295–301. DOI: https://doi.org/10.1016/j.it.2008.02.010
Van Lingen R, Van De Kerkhof P, Seyger M, De Jong E, Van Rens D, Poll M, et al. CD26/dipeptidyl-peptidase IV in psoriatic skin: upregulation and topographical changes. Br J Dermatol 2008; 158: 1264–1272. DOI: https://doi.org/10.1111/j.1365-2133.2008.08515.x
Chiu H-Y, Huang Y-H. Dipeptidyl peptidase-4 inhibitors and the risk of chronic inflammatory skin diseases in type 2 diabetes mellitus in Taiwan: a nationwide population-based cohort study. J Invest Dermatol 2024; 144: 2321–2324. DOI: https://doi.org/10.1016/j.jid.2024.03.017
Kridin K, Amber K, Khamaisi M, Comaneshter D, Batat E, Cohen AD. Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study. Immunol Res 2018; 66: 425–430. DOI: https://doi.org/10.1007/s12026-018-9005-8
Nishioka T, Shinohara M, Tanimoto N, Kumagai C, Hashimoto K. Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis. Dermatology 2012; 224: 20–21. DOI: https://doi.org/10.1159/000333358
Lynch M, Malara A, Timoney I, Ahern T, Awdeh F, -Sweeney C, et al. Dipeptidyl peptidase-4 inhibition in psoriasis patients with diabetes: a double-blind randomized controlled trial. Dermatology 2021; 237: 66–69. DOI: https://doi.org/10.1159/000502130
Kim SC, Schneeweiss S, Glynn RJ, Doherty M, Goldfine AB, Solomon DH. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. Ann Rheum Dis 2015; 74: 1968–1975. DOI: https://doi.org/10.1136/annrheumdis-2014-205216
Lynch M, Ahern TB, Timoney I, Sweeney C, Kelly G, Hughes R, et al. Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial. Trials 2016; 17: 1–10. DOI: https://doi.org/10.1186/s13063-016-1157-z
Cheng CL, Lee CH, Chen PS, Li YH, Lin SJ, Yang YH. Validation of acute myocardial infarction cases in the national health insurance research database in taiwan. J Epidemiol 2014; 24: 500–507. DOI: https://doi.org/10.2188/jea.JE20140076
Cheng CL, Chien HC, Lee CH, Lin SJ, Yang YH. Validity of in-hospital mortality data among patients with acute myocardial infarction or stroke in National Health Insurance Research Database in Taiwan. Int J Cardiol 2015; 201: 96–101. DOI: https://doi.org/10.1016/j.ijcard.2015.07.075
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383. DOI: https://doi.org/10.1016/0021-9681(87)90171-8
Lynch M, Tobin AM, Ahern T, O’Shea D, Kirby B. Sitagliptin for severe psoriasis. Clin Exp Dermatol 2014; 39: 841–842. DOI: https://doi.org/10.1111/ced.12408
Chen Y-C, Chen T-H, Sun C-C, Chen J-Y, Chang S-S, Yeung L, et al. Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohort study. Acta Diabetol 2020; 57: 1181–1192. DOI: https://doi.org/10.1007/s00592-020-01533-5
Feng J, Zhang Z, Wallace MB, Stafford JA, Kaldor SW, Kassel DB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 2007; 50: 2297–2300. DOI: https://doi.org/10.1021/jm070104l
Shao Z, Li X, Xu X, Chen P. DPP-4 inhibitor linagliptin ameliorates imiquimod-induced psoriasis-like skin alterations in type 2 diabetic mice by inhibiting the MAPK/NF-κB inflammatory pathway. Drug Dev Res 2022; 83: 1373–1382. DOI: https://doi.org/10.1002/ddr.21966
Mellor LF, Gago-Lopez N, Bakiri L, Schmidt FN, Busse B, Rauber S, et al. Keratinocyte-derived S100A9 modulates neutrophil infiltration and affects psoriasis-like skin and joint disease. Ann Rheum Dis 2022; 81: 1400–1408. DOI: https://doi.org/10.1136/annrheumdis-2022-222229
Xu F, Cui YZ, Yang XY, Zheng YX, Chen XB, Zhou H, et al. CXCL10 secreted by SPRY1-deficient epidermal keratinocytes fuels joint inflammation in psoriatic arthritis via CD14 signaling. J Clin Invest 2025; 135. DOI: https://doi.org/10.1172/JCI186135
Proost P, De Meester I, Schols D, Struyf S, Lambeir A-M, Wuyts A, et al. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV: conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem 1998; 273: 7222–7227. DOI: https://doi.org/10.1074/jbc.273.13.7222
Tian L, Gao J, Hao J, Zhang Y, Yi H, O’Brien TD, et al. Reversal of new-onset diabetes through modulating inflammation and stimulating β-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology 2010; 151: 3049–3060. DOI: https://doi.org/10.1210/en.2010-0068
Iskandar IYK, Chen TC, Chen LC, Lee MS, Yang YY, Wang TC, et al. Incidence, prevalence, and mortality of people with psoriasis and psoriatic arthritis in Taiwan: a nationwide cohort study. Acta Derm Venereol 2022; 102: adv00807. DOI: https://doi.org/10.2340/actadv.v102.1962
Jensen P, Ahlehoff O, Egeberg A, Gislason G, Hansen PR, Skov L. Psoriasis and new-onset depression: a Danish nationwide cohort study. Acta Derm Venereol 2016; 96: 39–42. DOI: https://doi.org/10.2340/00015555-2183
Downloads
Published
How to Cite
License
Copyright (c) 2025 Chih-Tsung Hung, Chi-Hsiang Chung, Tsu-Hsuan Weng, Chun-Teng Tsai, Wu-Chien Chien, Yung-Lung Chang
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
